Sugi Predict

Sugi Predict / Compounds / SCHEMBL17283142

SCHEMBL17283142

SCHEMBL17283142

C=CCc1cc(N(Cc2ccc(OC)cc2)Cc2ccc(OC)cc2)ncc1C(=C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ LMNA P02545 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ ADRA2A P08913 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ DRD1 P21728 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ SLC6A4 P31645 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15464787 0.83 ALDH1A1 (0.46) ALDH1A1CYP3A4TSHRSMN1; SMN2TP53
SCHEMBL17283150 0.81 LMNA (0.40) ALDH1A1CYP3A4TSHRSMN1; SMN2MEN1
SCHEMBL24574139 0.73 LMNA (0.43) ALDH1A1CYP3A4TSHRSMN1; SMN2MEN1
SCHEMBL29302732 0.73 LMNA (0.47) ALDH1A1CYP3A4TSHRSMN1; SMN2TP53
SCHEMBL15464409 0.71 LMNA (0.40) ALDH1A1CYP3A4TSHRSMN1; SMN2TP53
SCHEMBL18398181 0.70 HDAC3 (0.43) ALDH1A1CYP3A4TSHRSMN1; SMN2MEN1
SCHEMBL26977893 0.70 ALDH1A1 (0.47) ALDH1A1CYP3A4TSHRSMN1; SMN2TP53
SCHEMBL8232915 0.70 ALDH1A1 (0.47) ALDH1A1CYP3A4TSHRSMN1; SMN2TP53
SCHEMBL28903971 0.69 NPC1 (0.51) ALDH1A1CYP3A4TSHRSMN1; SMN2MEN1
SCHEMBL22491166 0.69 HSP90AA1 (0.49) ALDH1A1CYP3A4TSHRSMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3145915-B1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC (US) 2025-03-19 — — EP disclosed
US-10000454-B2 Antidiabetic tricyclic compounds MERCK SHARP & DOHME (US) 2018-06-19 — — US disclosed
US-10000454-B2 Antidiabetic tricyclic compounds MERCK SHARP & DOHME (US) 2018-06-19 — — US disclosed
US-10000454-B2 Antidiabetic tricyclic compounds MERCK SHARP & DOHME (US) 2018-06-19 — — US disclosed
US-20170081287-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC 2017-03-23 — — US disclosed
US-20170081287-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC 2017-03-23 — — US disclosed
US-20170081287-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC 2017-03-23 — — US disclosed
WO-2015176640-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2015-11-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000454-B2 Antidiabetic tricyclic compounds GPR119, GPR65, GPR52 ALDH1A1 3081/4885CYP3A4 1122/4885TSHR 351/4885
US-20170081287-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS GPR119, GPR65, GPR52 ALDH1A1 3081/4885CYP3A4 1122/4885TSHR 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.